# AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

> **NCT05594914** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of University of South China** · enrollment: 47 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** AK104

## Key facts

- **NCT ID:** NCT05594914
- **Lead sponsor:** The First Affiliated Hospital of University of South China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05594914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05594914, "AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05594914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*